Author details

Full Name

Brandon W Higgs

Affiliation

Translational and Clinical Data Sciences

ORCID

Career Start Year

2006

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37572794	Biliary atresia is associated with polygenic susceptibility in ciliogenesis and planar polarity effector genes.	J Hepatol	2023
37572794	Biliary atresia is associated with polygenic susceptibility in ciliogenesis and planar polarity effector genes.	J Hepatol	2023
34645581	The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients.	Clin Lung Cancer	2022
35492246	A network-based approach to identify expression modules underlying rejection in pediatric liver transplantation.	Cell Rep Med	2022
34645581	The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients.	Clin Lung Cancer	2022
35492246	A network-based approach to identify expression modules underlying rejection in pediatric liver transplantation.	Cell Rep Med	2022
33355200	A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.	Clin Cancer Res	2021
33972936	Impaired T-cell and antibody immunity after COVID-19 infection in chronically immunosuppressed transplant recipients.	bioRxiv	2021
33257508	A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade.	Mol Cancer Res	2021
33355200	A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.	Clin Cancer Res	2021
34845204	High-throughput mediation analysis of human proteome and metabolome identifies mediators of post-bariatric surgical diabetes control.	Nat Commun	2021
34845204	High-throughput mediation analysis of human proteome and metabolome identifies mediators of post-bariatric surgical diabetes control.	Nat Commun	2021
33972936	Impaired T-cell and antibody immunity after COVID-19 infection in chronically immunosuppressed transplant recipients.	bioRxiv	2021
33257508	A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade.	Mol Cancer Res	2021
32461104	Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.	Ann Oncol	2020
31657119	CD154-expressing CMV-specific T cells associate with freedom from DNAemia and may be protective in seronegative recipients after liver or intestine transplantation.	Pediatr Transplant	2020
32461104	Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.	Ann Oncol	2020
32271377	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.	JAMA Oncol	2020
33315971	Selective amplification of hypermethylated DNA from diverse tumor types via MSRE-PCR.	Oncotarget	2020
33192543	Biliary-Atresia-Associated Mannosidase-1-Alpha-2 Gene Regulates Biliary and Ciliary Morphogenesis and Laterality.	Front Physiol	2020
31657119	CD154-expressing CMV-specific T cells associate with freedom from DNAemia and may be protective in seronegative recipients after liver or intestine transplantation.	Pediatr Transplant	2020
33315971	Selective amplification of hypermethylated DNA from diverse tumor types via MSRE-PCR.	Oncotarget	2020
33192543	Biliary-Atresia-Associated Mannosidase-1-Alpha-2 Gene Regulates Biliary and Ciliary Morphogenesis and Laterality.	Front Physiol	2020
32271377	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.	JAMA Oncol	2020
30352801	Improved Therapeutic Window in <i>BRCA</i>-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.	Mol Cancer Ther	2019
30352801	Improved Therapeutic Window in <i>BRCA</i>-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.	Mol Cancer Ther	2019
31060602	Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.	J Immunother Cancer	2019
30778251	The transcription factor c-Myb regulates CD8<sup>+</sup> T cell stemness and antitumor immunity.	Nat Immunol	2019
31327642	Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.	Clin Lung Cancer	2019
31327642	Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.	Clin Lung Cancer	2019
30778251	The transcription factor c-Myb regulates CD8<sup>+</sup> T cell stemness and antitumor immunity.	Nat Immunol	2019
31060602	Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.	J Immunother Cancer	2019
29069507	Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.	Rheumatology (Oxford)	2018
29956883	Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease ActivityÂ in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.	Arthritis Rheumatol	2018
30093454	Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.	Clin Cancer Res	2018
29716923	Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.	Clin Cancer Res	2018
29243222	Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma.	Clin Pharmacol Ther	2018
29069507	Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.	Rheumatology (Oxford)	2018
30093454	Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.	Clin Cancer Res	2018
29956883	Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease ActivityÂ in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.	Arthritis Rheumatol	2018
29716923	Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.	Clin Cancer Res	2018
29243222	Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma.	Clin Pharmacol Ther	2018
26950712	Predicting Cellular Rejection With a Cell-Based Assay: Preclinical Evaluation in Children.	Transplantation	2017
28833989	Synergistic immunosuppression and unintended consequences.	Pediatr Transplant	2017
29242501	High-throughput RNA sequencing reveals distinct gene signatures in active IgG4-related disease.	Sci Rep	2017
26950712	Predicting Cellular Rejection With a Cell-Based Assay: Preclinical Evaluation in Children.	Transplantation	2017
27923825	Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.	Cancer Immunol Res	2017
29242501	High-throughput RNA sequencing reveals distinct gene signatures in active IgG4-related disease.	Sci Rep	2017
28833989	Synergistic immunosuppression and unintended consequences.	Pediatr Transplant	2017
27923825	Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.	Cancer Immunol Res	2017

1 - 50 of 186

Ang Cui

Massachusetts Institute of Technology

Career Start Year 2013

Number of shared co-authors 0

Jaclyn N Taroni

Alex's Lemonade Stand Foundation

Career Start Year 2013

Number of shared co-authors 1

Alexander F Rosenberg

University of Alabama at Birmingham Birmingham

Career Start Year 2011

Number of shared co-authors 0

Jinguo Chen

Center for Human Immunology

Career Start Year 2011

Number of shared co-authors 0

Nicolas Tchitchek

Sorbonne University INSERM

Career Start Year 2010

Number of shared co-authors 0

Vinod Kumar

The University of Queensland

Career Start Year 2008

Number of shared co-authors 0

Maggie Cam

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Career Start Year 2005

Number of shared co-authors 3

Agnes C Paquet

Universite Cote d'Azur, CNRS UMR5

Career Start Year 2004

Number of shared co-authors 0

Nathalie Pochet

Broad Institute of MIT and Harvard

Career Start Year 2004

Number of shared co-authors 0

Andrew V Kossenkov

The Wistar Institute

Career Start Year 2003

Number of shared co-authors 0

Michael Slifker

Fox Chase Cancer Center

Career Start Year 2002

Number of shared co-authors 0

Olivier Elemento

Meyer Cancer Center

Career Start Year 2002

Number of shared co-authors 0

Purvesh Khatri

University of California San Francisco

Career Start Year 2002

Number of shared co-authors 1

Ludmila Danilova

Bloomberg-Kimmel Immunotherapy Institute, Johns Hopkins University School of Medicine

Career Start Year 2001

Number of shared co-authors 0

Mikhail G Dozmorov

Virginia Commonwealth University

Career Start Year 2001

Number of shared co-authors 1

David K Crossman

University of Alabama at Birmingham

Career Start Year 2000

Number of shared co-authors 0

Yan W Asmann

Mayo Clinic

Career Start Year 2000

Number of shared co-authors 0

Shawn Levy

HudsonAlpha Institute for Biotechnology

Career Start Year 1999

Number of shared co-authors 3

Andrey Loboda

Merck & Co., Inc.

Career Start Year 1998

Number of shared co-authors 2

Lianbo Yu

The Ohio State University

Career Start Year 1997

Number of shared co-authors 0

Shannon K McWeeney

Oregon Health & Science University, University of California Berkeley

Career Start Year 1997

Number of shared co-authors 0

Clifton L Dalgard

Uniformed Services University of the Health Sciences

Career Start Year 1997

Number of shared co-authors 1

Seunghee Kim-Schulze

Icahn School of Medicine at Mount Sinai

Career Start Year 1996

Number of shared co-authors 0

Jenny Xiang

Caryl and Israel Englander Institute for Precision Medicine.

Career Start Year 1993

Number of shared co-authors 0

Atul J Butte

Bakar Computational Health Sciences Institute, University of California san francisco

Career Start Year 1993

Number of shared co-authors 2

Ping Jin

Center for Cellular Engineering, National Institutes of Health Clinical Center

Career Start Year 1993

Number of shared co-authors 4

Nan Deng

Cedars-Sinai Medical Center

Career Start Year 1992

Number of shared co-authors 0

Nir Hacohen

Broad Institute of MIT and Harvard

Career Start Year 1989

Number of shared co-authors 0

Richard H Scheuermann

J. Craig Venter Institute

Career Start Year 1983

Number of shared co-authors 2

Sean Davis

Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington

Career Start Year 1974

Number of shared co-authors 8

row(s) 1 - 30 of 30